nereus
Generic: tradipitant
nereus: developed by 1 company · 2 FDA decisions. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | Phase 3 |
FDA Decisions
FDA_MeetingFDA accepted the NDA for tradipitant for motion sickness with a PDUFA target date of December 30, 2025.(VNDA)
Approval1 INDICATIONS AND USAGE NEREUS is indicated for the prevention of vomiting induced by motion in adults. NEREUS is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for the prevention of vomiting induced by motion in adults. ( 1 )(VNDA)
Frequently asked questions
Who is developing nereus?
nereus is being developed by Vanda Pharmaceuticals Inc..
What is nereus's latest FDA decision?
The most recent tracked FDA decision for nereus is FDA_Meeting for FDA accepted the NDA for tradipitant for motion sickness with a PDUFA target date of December 30, 2025..
Get deeper analysis on nereus
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis